Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO business aims for volume growth of 4%-5% to achieve approx. CDMO business volume growth expected at 4-5% in near term, targeting overall revenue growth of 12-13%.
From Akums Drugs & Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO business aims for volume growth of 4%-5% to achieve approx. 12%-13% revenue growth.
- Historically, the company has achieved 6%-8% volume growth annually, 2-2.5x higher than the market.
- Recent 12-month trailing volume growth in CDMO is 1.6%, while industry was flat.
- Q4 and Q1 outlook for CDMO volume growth appears positive with visible order book.
- New European CDMO contract expected to contribute revenues starting CY 2027, spread evenly over contract length till 2032.
- API business is rationalizing portfolio, aiming for breakeven in 1 to 2 years.
- Focus on higher-margin and regulated market products to improve API revenues.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- incurred capex of INR 191 crores in 9 months of FY '25, largely in the CDMO vertical
- planned capex of INR 175-200 crores annually over next 2 years to commission new plants and production lines
- INR 32 crores capex over next 2 quarters to upgrade and improve R&D capabilities, focusing on regulated markets and niche dosage forms
- expanding and increasing manufacturing capabilities for nasal sprays, eye drops, bi-layered tablets, ampoules, FFS small volume parenterals
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has visibility on its order book for the next 60 days (Q4 FY25) and expects decent volume growth in this quarter.
- New contracts discussed earlier are expected to commercialize starting calendar year 2027 (likely Q4 2027 or Q1 next fiscal).
- The recently signed European contract worth EUR 200 million is expected to commence revenues in CY 2027 and will be spread evenly across years.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q3 FY25 results?
CDMO business aims for volume growth of 4%-5% to achieve approx. CDMO business volume growth expected at 4-5% in near term, targeting overall revenue growth of 12-13%.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
incurred capex of INR 191 crores in 9 months of FY '25, largely in the CDMO vertical - planned capex of INR 175-200 crores annually over next 2 years to commission new plants and production lines
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.